Impel Pharmaceuticals is a company that focuses on developing and providing transformative therapies for people suffering from diseases with high unmet medical needs through the pioneering of an optimized approach to drug delivery. They are the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations, which have the potential to improve the onset of symptomatic relief for a spectrum of conditions.
Location: United States, Washington, Seattle
Employees: 51-200
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Norwest Ve... | nvp.com |
| 04.03.2023 | Kohlberg K... | kkr.com |
Mentions in press and media 6
| Date | Title | Description |
| 15.12.2025 | nevity Secures $20M to Pioneer Cell Reprogramming for Metabolic Disease | Junevity, a San Francisco biotech firm, just raised $20 million in seed funding. This investment fuels development of its lead drug, JUN_01. JUN_01 targets type 2 diabetes and obesity using a novel siRNA approach. The company’s RESET platfo... |
| 11.12.2025 | Junevity: Seed Round Expanded To $20 Million To Advance siRNA Reprogramming Candidate Toward Clinical Trials | Junevity has expanded its seed financing to $20 million following a new $10 million investment led by Goldcrest Capital and Godfrey Capital. The San Francisco-based biotechnology company is developing therapeutics that use siRNA to reprogra... |
| 01.03.2025 | Junevity: Pioneering the Future of Longevity with $10 Million Seed Funding | In the bustling heart of San Francisco, a biotechnology company named Junevity is making waves. With a mission to extend both lifespan and healthspan, Junevity has successfully raised $10 million in seed funding. This financial boost, led b... |
| 27.02.2025 | Junevity: $10 Million (Seed) Raised For Developing Cell Reset Therapeutics For Longevity | Junevity – a biotechnology company on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases – announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital. Junevity’s RESET plat... |
| 14.02.2025 | Junevity: $10 Million (Seed) Raised For Developing Cell Reset Therapeutics For Longevity | Junevity, a biotechnology company that aims to extend lifespan and health by resetting cell damage from age-related diseases, announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital. The Junevity RESET platform is... |
| 05.05.2023 | Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023 | SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. IMPL, a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it wi... |